Abstract
Ticlopidine and abciximab are two antiplatelet agents that are frequently administered during percutaneous coronary interventions. Although they have different mechanisms of action and pharmacological profiles, the two agents are often concomitantly used in complicated stent placements. The purpose of the study was to evaluate the effect of ticlopidine therapy on the capacity of abciximab to inhibit platelet aggregation, in vitro. Blood samples from 13 ticlopidine-treated stent placement patients and 8 patients undergoing PTCA who did not receive ticlopidine were obtained prior to, 12–36 hours and 7–10 days after initiating ticlopidine treatment. For each patient, the minimal ADP and the thrombin receptor activating peptide (TRAP) concentrations that elicited maximal platelet aggregation responses at baseline were used to measure the extent of platelet aggregation and the abciximab concentration that gave a 50% decrease in aggregation (IC50) for both agonists at the three time points. The ticlopidine group baseline and 12–36 hour mean ADP aggregation responses were equivalent, but decreased by 34% (P = 0.009) at 7–10 days. The control group ADP and TRAP, as well as the ticlopidine group TRAP aggregation responses, were equivalent at all time points. The ticlopidine group baseline and 12–36 hour abciximab IC50 values for ADP were comparable (1.58 ± 1.1 ng/mL vs. 1.23 ± 0.5 ng/mL; P = 0.266), but decreased to 1.00 ± 0.6 ng/mL (36%; P = 0.004) at 7–10 days. In contrast, the abciximab IC50 for TRAP increased from 1.48 ± 1.0 ng/mL to 1.85 ± 1.1 ng/mL (25%; P = 0.033) at 12–36 hours, but returned to baseline at 7–10 days (1.40 ± 0.8; P = 0.975). The control group IC50 abciximab values for ADP and TRAP were comparable throughout the monitoring period. The results demonstrate that ticlopidine elicits subtle potentiation of the platelet-inhibitory capacity of abciximab to the agonist ADP, but not TRAP, at 1 week after initiation of treatment.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Schomig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996;334:1084–1089.
Hall P, Nakamura S, Maiello L, et al. A randomized comparison of combined ticlopidine and aspirin therapy versus aspirin therapy alone after successful intravascular ultrasound-guided stent implantation. Circulation 1996;93: 215–222.
Colombo A, Hall P, Nakamura S, et al., Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation 1995;91:1676–1688.
Di Minno G, Cerbone AM, Mattioli PL, Turco S, Iovine C, Mancini M. Functionally thrombasthenic state in normal platelets following the administration of titiclopidine. J Clin Invest 1985;75:328–338.
Kuzniar J, Splawinska B, Malinga K, Mazurek AP, Splawinski J. Pharmacodynamics of ticlopidine: Relation between dose and time of administration to platelet inhibition. Int. J Clin Pharm Ther 1996;34:357–361.
Buur T, Larsson R, Berglund U, Donat F, Tronquet C. Pharmacokinetics and effect of ticlopidine on platelet aggregation in subjects with normal and impaired renal function. J Clin Pharm 1997;37:108–15.
Heptinstall S, May JA, Glenn JR, Sanderson HM, Dickinson JP, Wilcox RG. Effects of ticlopidine administered to healthy volunteers on platelet function in whole blood. Thromb Haem 1995;74:1310–35.
Droste DW, Siemens HJ, Sonne M, Kaps M, Wagner T. Hemostaseologic and hematologic parameters with aspirin and ticlopidine treatment in patients with cerebrovascular disease — A cross-over study. J Card Pharm 1996;28:591–594.
The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330: 956–961.
Topol EJ, Califf RM, Weisman HF, et al. Randomized trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: Results at six months. Lancet 1994;343:1434–1435.
The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Eng J Med 1997;336: 1689–1696.
The Capture Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina — the Capture study. Lancet 1997;349:1429–1435.
Tcheng JE, Ellis SG, George BS, et al. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation 1994;90:1757–1764.
Kleiman NS, Raizner AE, Jordan R, et al. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: Implications for inhibition of the internal pool of GPIIb/IIIa receptors. J Am Coll Cardiol 1995;26:1665–1671.
Konstantopoulos K, Kamat SG, Schafer AI, et al. Shear-induced platelet aggregation is inhibited by in vivo infusion of an anti-glycoprotein IIb/IIIa antibody fragment, c7E3 Fab, in patients undergoing coronary angioplasty. Circulation 1995;91:1427–1431.
Vu T-KH, Wheaton VI, Hung DT, Charo I, Coughlin SR. Domains specifying thrombin receptor interaction. Nature 1991;353:674–677.
Born GVR. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962;194:927–929.
Defreyn G, Bernat A, Delebassee D, Maffrand JP. Pharmacology of ticlopidine: A review. Semir Thromb Hemo 1989;15:159–166.
Mascelli, MA, Worley S, Veriabo NJ, et al. Rapid assessment of platelet function using amodified whole blood aggregometer in PTCA patients receiving anti-GPIIb/IIIa therapy. Circulation 1997;96:3860–3866.
Mascelli, MA, Lance ET, Damaraju L, Wagner CL, Weisman HF, Jordan RE. The pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GPIIb/IIIa receptor blockade. Circulation 1998;97:1680–1688.
Gawaz M, Neumann FJ, Ott I, May A, Schomig A. Platelet activation and coronary stent implantation — Effect of antithrombotic therapy. Circulation 1996;94:279–285.
Tohgi H, Takahashi H, Kashiwaya M, Watanabe K. Effect of plasma fibrinogen concentration on the inhibition of platelet aggregation after ticlopidine compared with aspirin. Stroke 1994;25:2017–2021.
Gachet C, Cattaneo M, Ohlmann P, et al. Purinoceptors on blood platelets: Further pharmacological and clinical evidence to suggest the presence of two ADP receptors. Br J Haematol 1995;91:434–444.
Neumann FJ, Ott I, Gawaz M, Puchner G, Schomig A. Neutrophil and platelet activation at balloon-injured coronary artery plaque in patients undergoing angioplasty. J AmColl Cardiol 1996;27:819–824.
Scharf RE, Tomer A, Marzec UM, Teirstein PS, Ruggeri ZM, Harker LA. Activation of platelets in blood perfusing angioplasty-damaged coronary arteries: Flow cytometric detection. Arterioscler Thromb 1992;12:1475–1487.
Humbert M, Nurden P, Bihour C, et al. Ultrastructural studies of platelet aggregates from human subjects receiving clopidogrel and from a patient with an inherited defect of an ADP-dependent pathway of platelet activation. Arterioscler Thromb Vasc Biol 1996;16:1532–1543.
Cattaneo M, Lombardi R, Bettega D, Lecchi A, Mannucci PM. Shear-induced platelet aggregation is potentiated by desmopressin and inhibited by ticlopidine. Arteriocler Thromb 1993;13:393–397.
de Maat MP, Arnold AE, van Buuren S, Wilson JH, Kluft C. Modulation of plasma fibrinogen levels by ticlopidine in healthy volunteers and patients with stable angina pectoris. Thromb Haemost 1996;76:166–170.
Gryglewski RJ, Korbut R, Swies J, Kostka Trabka E, Bieron K, Robak J. Thrombolytic action of ticlopidine: Possible mechanisms. Eur J Pharm 1996;308:61–67.
Nurden P, Bihour C, Smith M, Raymond JM, Nurden AT. Platelet activation and thrombosis — Studies in a patient with essential thrombocythemia. Am J Hematol 1996;51: 79–84.
Gregorini L, Marco J, Fajadet J, et al. Ticlopidine and aspirin pretreatment reduces coagulation and platelet activation during coronary dilation procedures. J Am Coll Cardiol 1997;29:13–20.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kleiman, N.S., Graziadei, N., Jordan, R.E. et al. Ticlopidine Enhances the Platelet Inhibitory Capacity of Abciximab In Vitro. J Thromb Thrombolysis 9, 29–36 (2000). https://doi.org/10.1023/A:1018631810977
Issue Date:
DOI: https://doi.org/10.1023/A:1018631810977